Antidote — paracetamol overdose / Hepatoprotectant
Pregnancy: Safety in pregnancy has not been investigated in formal prospective clinical trials, but clinical experience indicates that use in pregnancy for the treatment of paracetamol overdose is effective; the potential risks should be balanced against the potential benefits prior to use. No information is available on excretion into breast milk, so breast-feeding is not advised during or immediately following use.
Acetylcysteine (N-acetylcysteine, NAC) is the specific antidote for paracetamol (acetaminophen) overdose, given by intravenous infusion in the emergency setting, and is also used as a mucolytic.
Auto-extracted from the source labelling — not yet independently clinician-verified. These values were distilled from the UK SPC (or the US label where noted) but have not had a clinician sign-off. Confirm against the current SmPC before prescribing.
Adult dose
Dose:Total 300 mg/kg over a 21 hour period, given as 3 consecutive intravenous infusions: (1) initial loading dose 150 mg/kg in 200 mL over 1 hour; (2) 50 mg/kg in 500 mL over the next 4 hours; (3) 100 mg/kg in 1 litre over the next 16 hours
Route: Intravenous infusion, preferably using Glucose 5% as the infusion fluid; Sodium Chloride 0.9% solution may be used if Glucose 5% is not suitable
Frequency: Single 21 hour course of three consecutive infusions. Continued treatment (given at the dose and rate used in the third infusion) may be necessary depending on the clinical evaluation of the individual patient
Max: A ceiling weight of 110 kg should be used when calculating the dosage for obese patients; at that ceiling the SPC prescription table gives 16,500 mg (dose 1), 5,500 mg (dose 2) and 11,000 mg (dose 3)
Indication (SPC §4.4): paracetamol overdose. Intravenous N-acetylcysteine given within 24 hours of ingestion of a potentially hepatotoxic overdose of paracetamol is indicated to prevent or reduce the severity of liver damage; it is most effective when administered within 8 to 10 hours of the overdose. Efficacy diminishes between 10 and 24 hours but it should still be administered up to 24 hours, and may still be administered after 24 hours in patients at risk of severe liver damage. Dosage should be calculated using the patient's actual weight (ceiling weight 110 kg in obesity). Doses are administered sequentially with no break between doses, using an appropriate infusion pump. Anaphylactoid reactions: these occur particularly with the initial loading dose; most can be managed by temporarily suspending the infusion, giving appropriate supportive care and restarting at a lower infusion rate — once controlled, the infusion can normally be restarted at 50 mg/kg over 4 hours followed by the final 100 mg/kg over 16 hours. Fluid and electrolytes: use with caution in children, in patients requiring fluid restriction and in those weighing less than 40 kg because of the risk of fluid overload, which may result in hyponatraemia and seizures; each 10 mL contains 322.6 mg sodium. Coagulation: an isolated rise in prothrombin time up to 1.3 at the end of a 21 hour course without elevated transaminase activity does not require further monitoring or further treatment. Monitoring of plasma potassium is recommended (hypokalaemia and ECG changes occur in paracetamol poisoning irrespective of treatment). Source: UK SPC for Acetylcysteine 200 mg/mL Injection (eMC product 3447).
Paediatric dose
Dose:150 mg/kg
Route: Intravenous infusion, preferably using Glucose 5%; Sodium Chloride 0.9% may be used if Glucose 5% is not suitable; administer using an appropriate infusion pump
Frequency: Initial loading infusion 150 mg/kg over 1 hour (150 mg/kg/h, given as a 50 mg/mL solution at 3 mL/kg/h), then 50 mg/kg over 4 hours (12.5 mg/kg/h, as a 6.25 mg/mL solution at 2 mL/kg/h), then 100 mg/kg over 16 hours (6.25 mg/kg/h, as a 6.25 mg/mL solution at 1 mL/kg/h) — three consecutive infusions given sequentially with no break
Max: The SPC paediatric prescription table covers weight bands from 1 kg up to 35-39 kg; the adult ceiling weight of 110 kg applies when calculating dosage in obesity
SPC §4.2 states: 'Children should be treated with the same doses and regimen as adults; however, the quantity of intravenous fluid used should be modified to take into account age and weight, as fluid overload is a potential danger.' The total course is 300 mg/kg over 21 hours (150 + 50 + 100 mg/kg). Preparation per SPC: dose 1 as a 50 mg/mL solution (dilute each 10 mL ampoule of 200 mg/mL with 30 mL glucose 5% or sodium chloride 0.9% to a total of 40 mL); doses 2 and 3 as a 6.25 mg/mL solution (dilute each 10 mL ampoule with 310 mL to a total of 320 mL). SPC worked example: for a child weighing 12 kg, 38 mL of solution is required for Dose 1 (infused at 38 mL/h over 60 minutes), 100 mL for Dose 2 (25 mL/h) and 200 mL for Dose 3 (13 mL/h). Caution: risk of fluid overload, hyponatraemia and seizures in children and in patients weighing less than 40 kg. Verify paediatric dosing and dilution against a children's formulary before administration.
Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.
Paediatric weight-based calculator
SPC §4.2 states: 'Children should be treated with the same doses and regimen as adults; however, the quantity of intravenous fluid used should be modified to take into account age and weight, as fluid overload is a potential danger.' The total course is 300 mg/kg over 21 hours (150 + 50 + 100 mg/kg). Preparation per SPC: dose 1 as a 50 mg/mL solution (dilute each 10 mL ampoule of 200 mg/mL with 30 mL glucose 5% or sodium chloride 0.9% to a total of 40 mL); doses 2 and 3 as a 6.25 mg/mL solution (dilute each 10 mL ampoule with 310 mL to a total of 320 mL). SPC worked example: for a child weighing 12 kg, 38 mL of solution is required for Dose 1 (infused at 38 mL/h over 60 minutes), 100 mL for Dose 2 (25 mL/h) and 200 mL for Dose 3 (13 mL/h). Caution: risk of fluid overload, hyponatraemia and seizures in children and in patients weighing less than 40 kg. Verify paediatric dosing and dilution against a children's formulary before administration.
SPC §4.3: 'There are no contraindications to the treatment of paracetamol overdose with N-acetylcysteine.'
Side effects
Nausea and vomiting (most common)
Flushing and skin rash; pruritus and urticaria
Anaphylactoid hypersensitivity reactions, particularly with the initial loading dose — angioedema, bronchospasm/respiratory distress, hypotension, tachycardia or hypertension (very rarely fatal); usually occurring 15 to 60 minutes after the start of infusion
Injection site reactions, cough, chest tightness or pain
Bradycardia, syncope, thrombocytopenia, generalised seizure and deterioration of liver function (other reported reactions)
Interactions
SPC §4.5: 'There are no known interactions.'
Clinical monograph
How it works
It replenishes hepatic glutathione stores (and provides cysteine), allowing detoxification of the reactive paracetamol metabolite NAPQI before it binds to and damages hepatocytes, thereby preventing or limiting paracetamol-induced hepatic necrosis.
Prescribing in practice
Treatment should be started promptly in significant paracetamol overdose, guided by the paracetamol nomogram and timing of ingestion, as efficacy is greatest when given early and benefit falls with delay.
Anaphylactoid reactions (flushing, rash, bronchospasm, hypotension) can occur, particularly during the initial infusion, and are managed by slowing or pausing the infusion and giving supportive treatment rather than necessarily abandoning the antidote.
Use with caution in patients with asthma given the risk of bronchospasm, and follow the current MHRA/UK guidance on infusion regimens and continuation criteria.
Monitoring
Monitor liver function tests, INR, renal function and the paracetamol concentration, with continuation of treatment guided by these results and the clinical course.
Counselling the patient
Explain that this is the antidote that protects the liver after a paracetamol overdose and works best when given early.
Warn that flushing or a rash during the infusion can occur and is managed by adjusting the infusion rate.
Encourage engagement with psychosocial assessment and follow-up after the overdose.
Evidence & guidelines
Intravenous acetylcysteine is the established standard-of-care antidote for paracetamol poisoning in UK practice, with use directed by the paracetamol treatment nomogram and national poisons guidance.
Reference: TOXBASE; MHRA Parvolex SPC 2019; NPIS guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing.
The structured dose values shown have been reviewed by a clinician.
Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.